The Importance of Tailored Education And Device Handling for Asthmatic Patients
ConditionAsthma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChiesi Hungary Ltd.
About this trial
Significant advancements have been made in asthma medication over the past decades. Highly effective treatments are available for patients; however, both adherence and proper device usage remain below the desired levels, based on our experience and literature data. Despite the availability of numerous excellent drug-device combinations, personalized treatment for patients is still not adequately addressed.
In the present study, the aim is to improve patient compliance and educate symptomatic, partially, or uncontrolled asthma patients on the correct use of a specific inhalation device (Nexthaler). Considering the characteristics of the medication, the patient's lung function data, inhalation technique, and drug retention time can help estimate the expected lung deposition of the medication. By refining the inhalation technique under the guidance of the treating physician, it is hypothesized that the expected therapeutic effects of the medication may improve.
Eligibility criteria
Qualifiers
Physician-confirmed clinical diagnosis of asthma according to GINA guidelines
Uncontrolled asthma according to the physician's clinical assessment despite the use of appropriate therapy of Step 2 or 3, according to GINA guidelines
Patients who are eligible for the use of Foster Nexthaler 100/6 mcg according to the SmPC
Inhaled asthma therapy was changed independent from the study to Foster Nexthaler 100/6 mcg DPI maximum 1 week prior to OR on the day of study inclusion
Disqualifiers
Participation in any clinical trial, 30 days prior to inclusion
Patient is unable to execute a spirometry test
Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment.
Patients with other significant diseases of the respiratory system or other organ systems that may significantly contribute to asthma symptoms (such as severe heart failure, symptomatic anaemia, functional respiratory disorders, malignant diseases etc.) according to the physician's clinical assessment.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
250 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov